Avacta : Notice of Results

26 September 2016

Avacta Group plc

('Avacta' or 'the Group' or 'the Company')

Notice of Results

Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, will announceits financial results for the year ended 31 July 2016 on Monday, 17 October 2016.

ENDS

Notes to Editors

For further information from Avacta Group plc, please contact:

About Avacta Group plc(www.avacta.com)

Avacta's principal focus is on its proprietary Affimer technology which is anovel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $75bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology isbased on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets to enable diagnostics, research assays and therapeutics.

Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.